INVITRO INTRINSIC RADIATION SENSITIVITY OF GLIOBLASTOMA-MULTIFORME

被引:95
|
作者
TAGHIAN, A
SUIT, H
PARDO, F
GIOIOSO, D
TOMKINSON, K
DUBOIS, W
GERWECK, L
机构
[1] Edwin L. Steele Laboratory of Radiation Biology, Department of Radiation Oncology, Massachusetts General Hospital, Boston
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1992年 / 23卷 / 01期
关键词
INTRINSIC RADIOSENSITIVITY; SF2; MALIGNANT GLIOMA;
D O I
10.1016/0360-3016(92)90543-Q
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Glioblastoma multiforme is one of the most resistant of human tumors to radiation whether used alone or in combination with surgery and/or chemotherapy. This resistance may be caused by one or more of several different factors. These include inherent cellular radiation sensitivity, an efficient repair of radiation damage, an increased number of clonogens per unit of volume, a high hypoxic fraction, high [GSH] concentration, and rapid proliferation between fractions. In the present study, we evaluate the intrinsic radiation sensitivity (surviving fraction at 2 Gy or mean inactivation dose) of malignant human glioma cells in vitro. The in vitro radiation sensitivity of 21 malignant glioma cell lines (early and long term passages) has been measured using colony formation as the end-point of cell viability. The survival curve parameters (SF2 measured and calculated, alpha, beta, D0, n approximately, and MID) have been determined for single dose irradiations of exponential phase cells (18-24 hr after plating) under aerobic conditions and growing on plastic. The mean SF2 of the 21 cell lines is 0.51 +/- 0.14 (with a range of 0.19 to 0.76). This value may be compared to the mean SF2 of 0.43-0.47 for SCC, 0.43 for melanoma, and 0.52 for glioblastoma as reported from other authors when using colony formation of cells in exponential phase on plastic. Although glioblastoma is almost invariably fatal, our data demonstrate a very wide range of intrinsic radiosensitivities. These broadly overlap the radiation sensitivities of cell lines from tumors that are often treated successfully. We conclude that standard in vitro measurements of cellular radiation sensitivity (SF2) do not yield values that track in a simple manner with local control probability at the clinical level and that, for at least some of the tumors, other parameters and/or physiological factors are more important.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 50 条
  • [41] The Impact of Surgery on the Efficacy of Adjuvant Therapy in Glioblastoma Multiforme
    Brzozowska, Anna
    Torun, Anna
    Mazurkiewicz, Maria
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 24 (02): : 279 - 287
  • [42] Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme
    Easaw, J. C.
    Mason, W. P.
    Perry, J.
    Laperriere, N.
    Eisenstat, D. D.
    Del Maestro, R.
    Belanger, K.
    Fulton, D.
    Macdonald, D.
    CURRENT ONCOLOGY, 2011, 18 (03) : E126 - E136
  • [43] Primary glioblastoma multiforme of the conus medullaris with leptomeningeal metastasis
    Nunn, Adam
    Polyzoidis, Stavros
    Piechowski-Jozwiak, Bartlomiej
    Brazil, Lucy
    Ashkan, Keyoumars
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 315 - 317
  • [44] Recent therapeutic advances and insights of recurrent glioblastoma multiforme
    Chen, Juxiang
    Xu, Tao
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2013, 18 : 676 - 684
  • [45] Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival
    Ewelt, Christian
    Goeppert, Mathias
    Rapp, Marion
    Steiger, Hans-Jakob
    Stummer, Walter
    Sabel, Michael
    JOURNAL OF NEURO-ONCOLOGY, 2011, 103 (03) : 611 - 618
  • [46] Carmustin implants during multimodal therapy of Glioblastoma multiforme
    Goelz, L.
    Gutowski, P.
    Lemcke, J.
    Graewe, A.
    Meier, U.
    NERVENHEILKUNDE, 2013, 32 (10) : 772 - 777
  • [47] Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme
    Briceno, Eduardo
    Calderon, Alejandra
    Sotelo, Julio
    SURGICAL NEUROLOGY, 2007, 67 (04): : 388 - 391
  • [48] Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology
    Rezaei, Vahid
    Rabiee, Amir
    Khademi, Farzaneh
    JOURNAL OF CHEMOTHERAPY, 2020, 32 (03) : 107 - 117
  • [49] Time trends in glioblastoma multiforme survival: the role of temozolomide
    Dubrow, Robert
    Darefsky, Amy S.
    Jacobs, Daniel I.
    Park, Lesley S.
    Rose, Michal G.
    Laurans, Maxwell S. H.
    King, Joseph T., Jr.
    NEURO-ONCOLOGY, 2013, 15 (12) : 1750 - 1761
  • [50] Targeted drug delivery for treatment and imaging of glioblastoma multiforme
    Stukel, Jill M.
    Caplan, Michael R.
    EXPERT OPINION ON DRUG DELIVERY, 2009, 6 (07) : 705 - 718